{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:49:44Z","timestamp":1790232584377,"version":"4.1.0"},"reference-count":93,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>MYC is a potent oncogene initially identified as the target of the t(8;14)(q24;q32) chromosome translocation in Burkitt lymphoma. MYC gene alterations have been identified in other mature B-cell neoplasms that are usually associated with an aggressive clinical behavior. Most of these tumors originate in cells that do not normally express MYC protein. The oncogenic events leading to MYC up-regulation seem to overcome the inhibitory effect of physiological repressors such as BCL6 or BLIMP1. Aggressive lymphomas frequently carry additional oncogenic alterations that cooperate with MYC dysregulation, likely counteracting its proapoptotic function. The development of FISH probes and new reliable antibodies have facilitated the study of MYC gene alterations and protein expression in large series of patients, providing new clinical and biological perspectives regarding MYC dysregulation in aggressive lymphomas. MYC gene alterations in large B-cell lymphomas are frequently associated with BCL2 or BCL6 translocations conferring a very aggressive behavior. Conversely, MYC protein up-regulation may occur in tumors without apparent gene alterations, and its association with BCL2 overexpression also confers a poor prognosis. In this review, we integrate all of this new information and discuss perspectives, challenges, and open questions for the diagnosis and management of patients with MYC-driven aggressive B-cell lymphomas.<\/jats:p>","DOI":"10.1182\/asheducation-2013.1.575","type":"journal-article","created":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T15:51:13Z","timestamp":1386345073000},"page":"575-583","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":51,"title":["Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification"],"prefix":"10.1182","volume":"2013","author":[{"given":"German","family":"Ott","sequence":"first","affiliation":[{"name":"Department of Clinical Pathology, Robert-Bosch-Krankenhaus, and Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Rosenwald","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University of W\u00fcrzburg, W\u00fcrzburg, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Campo","sequence":"additional","affiliation":[{"name":"Hematopathology Unit, Pathology Department, Hospital Cl\u00ednic and University of Barcelona, Institute of Biomedical Research August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2019111702591339400_B1","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/nrc2231","article-title":"Reflecting on 25 years with MYC","volume":"8","author":"Meyer","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2019111702591339400_B2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","article-title":"MYC on the path to cancer","volume":"149","author":"Dang","year":"2012","journal-title":"Cell"},{"issue":"4","key":"2019111702591339400_B3","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1365-2141.2010.08159.x","article-title":"Advances in the understanding of MYC-induced lymphomagenesis","volume":"149","author":"Klapproth","year":"2010","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111702591339400_B4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2012.06.012","article-title":"Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis","volume":"22","author":"Sander","year":"2012","journal-title":"Cancer Cell"},{"issue":"3","key":"2019111702591339400_B5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/gcc.10178","article-title":"Lymphoma- and leukemia-associated chromosomal translocations in healthy individuals","volume":"36","author":"Janz","year":"2003","journal-title":"Genes Chromosomes Cancer"},{"issue":"2","key":"2019111702591339400_B6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.gene.2011.12.027","article-title":"Regulation of gene transcription by the oncoprotein MYC","volume":"494","author":"Luscher","year":"2012","journal-title":"Gene"},{"issue":"10","key":"2019111702591339400_B7","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1038\/sj.emboj.7601691","article-title":"Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis","volume":"26","author":"Keller","year":"2007","journal-title":"EMBO J"},{"issue":"5","key":"2019111702591339400_B8","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.bbadis.2011.02.002","article-title":"MicroRNAs and the cell cycle","volume":"1812","author":"Bueno","year":"2011","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"2019111702591339400_B9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/ng.2007.30","article-title":"Widespread microRNA repression by Myc contributes to tumorigenesis","volume":"40","author":"Chang","year":"2008","journal-title":"Nat Genet"},{"issue":"4","key":"2019111702591339400_B10","doi-asserted-by":"crossref","first-page":"556","DOI":"10.4161\/cc.8.4.7599","article-title":"Repressing the repressor:a new mode of MYC action in lymphomagenesis","volume":"8","author":"Sander","year":"2009","journal-title":"Cell Cycle"},{"issue":"17","key":"2019111702591339400_B11","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1158\/0008-5472.CAN-09-1095","article-title":"MicroRNA expression, chromosomal alterations, and immunoglobulin variable heavy chain hypermutations in mantle cell lymphomas","volume":"69","author":"Navarro","year":"2009","journal-title":"Cancer Res"},{"issue":"11","key":"2019111702591339400_B12","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1038\/sj.leu.2403942","article-title":"A microRNA cluster as a target of genomic amplification in malignant lymphoma","volume":"19","author":"Tagawa","year":"2005","journal-title":"Leukemia"},{"issue":"24","key":"2019111702591339400_B13","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1038\/onc.2011.470","article-title":"Myc represses miR-15a\/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas","volume":"31","author":"Zhang","year":"2012","journal-title":"Oncogene"},{"issue":"4","key":"2019111702591339400_B14","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ccr.2012.09.003","article-title":"Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas","volume":"22","author":"Zhang","year":"2012","journal-title":"Cancer Cell"},{"issue":"22","key":"2019111702591339400_B15","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1038\/onc.2010.634","article-title":"Myc overexpression brings out unexpected antiapoptotic effects of miR-34a","volume":"30","author":"Sotillo","year":"2011","journal-title":"Oncogene"},{"key":"2019111702591339400_B16","article-title":"Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity","author":"Zhao","journal-title":"Leukemia"},{"issue":"1","key":"2019111702591339400_B17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cell.2012.09.006","article-title":"All things to all people","volume":"151","author":"Littlewood","year":"2012","journal-title":"Cell"},{"issue":"1","key":"2019111702591339400_B18","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cell.2012.08.033","article-title":"c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells","volume":"151","author":"Nie","year":"2012","journal-title":"Cell"},{"issue":"1","key":"2019111702591339400_B19","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cell.2012.08.026","article-title":"Transcriptional amplification in tumor cells with elevated c-Myc","volume":"151","author":"Lin","year":"2012","journal-title":"Cell"},{"issue":"3","key":"2019111702591339400_B20","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ccr.2005.08.005","article-title":"The great MYC escape in tumorigenesis","volume":"8","author":"Dang","year":"2005","journal-title":"Cancer Cell"},{"key":"2019111702591339400_B21","first-page":"139","article-title":"Small-molecule modulators of c-Myc\/Max and Max\/Max interactions","volume":"348","author":"Berg","year":"2011","journal-title":"Curr Top Microbiol Immunol"},{"key":"2019111702591339400_B22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0065-230X(10)07006-5","article-title":"MYC in oncogenesis and as a target for cancer therapies","volume":"107","author":"Albihn","year":"2010","journal-title":"Adv Cancer Res"},{"issue":"6","key":"2019111702591339400_B23","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"issue":"40","key":"2019111702591339400_B24","doi-asserted-by":"crossref","first-page":"16669","DOI":"10.1073\/pnas.1108190108","article-title":"Targeting MYC dependence in cancer by inhibiting BET bromodomains","volume":"108","author":"Mertz","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111702591339400_B25","article-title":"Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors","author":"Tolani","journal-title":"Oncogene"},{"issue":"2","key":"2019111702591339400_B26","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Loven","year":"2013","journal-title":"Cell"},{"issue":"11","key":"2019111702591339400_B27","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/ni.2418","article-title":"The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers","volume":"13","author":"Calado","year":"2012","journal-title":"Nat Immunol"},{"issue":"11","key":"2019111702591339400_B28","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/ni.2428","article-title":"The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry","volume":"13","author":"Dominguez-Sola","year":"2012","journal-title":"Nat Immunol"},{"issue":"5312","key":"2019111702591339400_B29","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1126\/science.276.5312.596","article-title":"Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation","volume":"276","author":"Lin","year":"1997","journal-title":"Science"},{"issue":"11","key":"2019111702591339400_B30","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood-2012-03-415380","article-title":"Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas","volume":"120","author":"Victora","year":"2012","journal-title":"Blood"},{"issue":"7418","key":"2019111702591339400_B31","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature11378","article-title":"Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics","volume":"490","author":"Schmitz","year":"2012","journal-title":"Nature"},{"issue":"11","key":"2019111702591339400_B32","doi-asserted-by":"crossref","first-page":"e26837","DOI":"10.1371\/journal.pone.0026837","article-title":"Deep sequencing of MYC DNA-binding sites in Burkitt lymphoma","volume":"6","author":"Seitz","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"2019111702591339400_B33","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/PAS.0b013e318244e2ba","article-title":"High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma","volume":"36","author":"Green","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"2019111702591339400_B34","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/path.4141","article-title":"MYC expression and distribution in normal mature lymphoid cells","volume":"229","author":"Cattoretti","year":"2013","journal-title":"J Pathol"},{"issue":"26","key":"2019111702591339400_B35","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1182\/blood-2012-06-437624","article-title":"Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes","volume":"120","author":"Giulino-Roth","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019111702591339400_B36","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/ng0993-56","article-title":"Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas","volume":"5","author":"Bhatia","year":"1993","journal-title":"Nat Genet"},{"issue":"6844","key":"2019111702591339400_B37","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/35085588","article-title":"Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas","volume":"412","author":"Pasqualucci","year":"2001","journal-title":"Nature"},{"issue":"7052","key":"2019111702591339400_B38","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/nature03845","article-title":"Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants","volume":"436","author":"Hemann","year":"2005","journal-title":"Nature"},{"issue":"23","key":"2019111702591339400_B39","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa055759","article-title":"Molecular diagnosis of Burkitt's lymphoma","volume":"354","author":"Dave","year":"2006","journal-title":"N Engl J Med"},{"issue":"23","key":"2019111702591339400_B40","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa055351","article-title":"A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling","volume":"354","author":"Hummel","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111702591339400_B41","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/ng.2469","article-title":"Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing","volume":"44","author":"Richter","year":"2012","journal-title":"Nat Genet"},{"issue":"12","key":"2019111702591339400_B42","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/ng.2468","article-title":"The genetic landscape of mutations in Burkitt lymphoma","volume":"44","author":"Love","year":"2012","journal-title":"Nat Genet"},{"issue":"12","key":"2019111702591339400_B43","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1038\/leu.2008.230","article-title":"Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)","volume":"22","author":"Klapper","year":"2008","journal-title":"Leukemia"},{"issue":"17","key":"2019111702591339400_B44","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","article-title":"MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy","volume":"114","author":"Savage","year":"2009","journal-title":"Blood"},{"key":"2019111702591339400_B45","article-title":"MYC protein expression and genetic alterations have prognostic impact in diffuse large B-cell lymphoma treated with immunochemotherapy","author":"Valera","journal-title":"Haematologica"},{"issue":"4","key":"2019111702591339400_B46","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/gcc.20187","article-title":"Amplification of IGH\/MYC fusion in clinically aggressive IGH\/BCL2-positive germinal center B-cell lymphomas","volume":"43","author":"Martin-Subero","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"issue":"4","key":"2019111702591339400_B47","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3324\/haematol.2009.012864","article-title":"Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma","volume":"95","author":"Stasik","year":"2010","journal-title":"Haematologica"},{"issue":"8","key":"2019111702591339400_B48","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1097\/01.pas.0000168176.71405.e5","article-title":"Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma","volume":"29","author":"Haralambieva","year":"2005","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"2019111702591339400_B49","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1182\/blood-2012-06-435842","article-title":"MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma","volume":"121","author":"Horn","year":"2013","journal-title":"Blood"},{"issue":"11","key":"2019111702591339400_B50","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","article-title":"Lymphomas with concurrent BCL2 and MYC translocations:the critical factors associated with survival","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"issue":"20","key":"2019111702591339400_B51","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","article-title":"Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab","volume":"28","author":"Barrans","year":"2010","journal-title":"J Clin Oncol"},{"issue":"14","key":"2019111702591339400_B52","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1200\/JCO.2010.32.8385","article-title":"The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective","volume":"29","author":"Salaverria","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111702591339400_B53","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/sj.leu.2404529","article-title":"Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas","volume":"21","author":"Bertrand","year":"2007","journal-title":"Leukemia"},{"issue":"4","key":"2019111702591339400_B54","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/leu.2008.344","article-title":"Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24\/c-MYC translocations","volume":"23","author":"Niitsu","year":"2009","journal-title":"Leukemia"},{"issue":"4","key":"2019111702591339400_B55","doi-asserted-by":"crossref","first-page":"e33813","DOI":"10.1371\/journal.pone.0033813","article-title":"Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas","volume":"7","author":"Kluk","year":"2012","journal-title":"PLoS One"},{"issue":"28","key":"2019111702591339400_B56","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111702591339400_B57","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/path.2410","article-title":"MYC translocation-negative classical Burkitt lymphoma cases:an alternative pathogenetic mechanism involving miRNA deregulation","volume":"216","author":"Leucci","year":"2008","journal-title":"J Pathol"},{"issue":"9","key":"2019111702591339400_B58","doi-asserted-by":"crossref","first-page":"e12960","DOI":"10.1371\/journal.pone.0012960","article-title":"Alteration of microRNAs regulated by c-Myc in Burkitt lymphoma","volume":"5","author":"Onnis","year":"2010","journal-title":"PLoS One"},{"issue":"20","key":"2019111702591339400_B59","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein co-expression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program Study","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"key":"2019111702591339400_B60","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue","author":"Swerdlow","year":"2008"},{"issue":"12","key":"2019111702591339400_B61","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1097\/01.pas.0000180442.87022.08","article-title":"Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior","volume":"29","author":"McClure","year":"2005","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"2019111702591339400_B62","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1038\/leu.2008.166","article-title":"Pathway activation patterns in diffuse large B-cell lymphomas","volume":"22","author":"Bentink","year":"2008","journal-title":"Leukemia"},{"issue":"10","key":"2019111702591339400_B63","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3324\/haematol.11305","article-title":"The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24\/c-MYC rearrangement","volume":"92","author":"Le Gouill","year":"2007","journal-title":"Haematologica"},{"issue":"3","key":"2019111702591339400_B64","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/PAS.0b013e3181cd3aeb","article-title":"B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma","volume":"34","author":"Snuderl","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"2019111702591339400_B65","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/modpathol.2011.147","article-title":"B-cell lymphomas with MYC\/8q24 rearrangements and IGH@BCL2\/t(14;18)(q32;q21):an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome","volume":"25","author":"Li","year":"2012","journal-title":"Mod Pathol"},{"issue":"9","key":"2019111702591339400_B66","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3324\/haematol.2011.042531","article-title":"Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles","volume":"96","author":"Horn","year":"2011","journal-title":"Haematologica"},{"issue":"21","key":"2019111702591339400_B67","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1056\/NEJM198805263182106","article-title":"Activation of the c-myc oncogene in a precursor-B-cell blast crisis of follicular lymphoma, presenting as composite lymphoma","volume":"318","author":"De Jong","year":"1988","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111702591339400_B68","first-page":"431","article-title":"Pre-B-cell leukemia with a t(8;14) and a t(14;18) translocation is preceded by follicular lymphoma","volume":"2","author":"Gauwerky","year":"1988","journal-title":"Oncogene"},{"key":"2019111702591339400_B69","unstructured":"Mitelman F Johansson B Mertens F Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer Accessed April 4, 2013 Available from: http:\/\/cgap.nci.nih.gov\/Chromosomes\/Mitelman"},{"issue":"8","key":"2019111702591339400_B70","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood-2010-09-297879","article-title":"Double-hit B-cell lymphomas","volume":"117","author":"Aukema","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2019111702591339400_B71","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/PAS.0b013e31826cebad","article-title":"Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas","volume":"37","author":"Pillai","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"2019111702591339400_B72","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/01.pas.0000126781.87158.e3","article-title":"Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities","volume":"28","author":"Colomo","year":"2004","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"2019111702591339400_B73","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1097\/PAS.0b013e3181f3e29f","article-title":"IG\/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas","volume":"34","author":"Valera","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"2019111702591339400_B74","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/j.1365-2559.2012.04339.x","article-title":"Plasmablastic lymphoma of the elderly:a clinicopathological comparison with age-related Epstein-Barr virus-associated B cell lymphoproliferative disorder","volume":"61","author":"Liu","year":"2012","journal-title":"Histopathology"},{"issue":"4","key":"2019111702591339400_B75","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1309\/AJCPFUR1BK0UODTS","article-title":"Plasmablastic lymphomas with MYC\/IgH rearrangement: report of three cases and review of the literature","volume":"132","author":"Bogusz","year":"2009","journal-title":"Am J Clin Pathol"},{"issue":"21","key":"2019111702591339400_B76","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1002\/cncr.27551","article-title":"Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy","volume":"118","author":"Castillo","year":"2012","journal-title":"Cancer"},{"issue":"10","key":"2019111702591339400_B77","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1172\/JCI61188","article-title":"Molecular pathogenesis of multiple myeloma and its premalignant precursor","volume":"122","author":"Kuehl","year":"2012","journal-title":"J Clin Invest"},{"issue":"10","key":"2019111702591339400_B78","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1182\/blood.V98.10.3082","article-title":"Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors","volume":"98","author":"Avet-Loiseau","year":"2001","journal-title":"Blood"},{"issue":"7","key":"2019111702591339400_B79","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/gcc.20563","article-title":"Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors","volume":"47","author":"Gabrea","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"issue":"12","key":"2019111702591339400_B80","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood-2011-08-371567","article-title":"Addiction to c-MYC in multiple myeloma","volume":"120","author":"Holien","year":"2012","journal-title":"Blood"},{"issue":"12","key":"2019111702591339400_B81","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/blood-2012-08-445262","article-title":"MYC addiction: a potential therapeutic target in MM","volume":"120","author":"Kuehl","year":"2012","journal-title":"Blood"},{"issue":"7","key":"2019111702591339400_B82","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/modpathol.2010.72","article-title":"Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features","volume":"23","author":"Taddesse-Heath","year":"2010","journal-title":"Mod Pathol"},{"issue":"6","key":"2019111702591339400_B83","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1309\/AJCPWY1SGJ9IEAOR","article-title":"Transformation of follicular lymphoma to plasmablastic lymphoma with c-myc gene rearrangement","volume":"134","author":"Ouansafi","year":"2010","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"2019111702591339400_B84","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/PAS.0b013e31826cb1d1","article-title":"Plasmablastic transformation of low-grade B-cell lymphomas: report on 6 cases","volume":"37","author":"Martinez","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"2019111702591339400_B85","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.3324\/haematol.2009.016113","article-title":"Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype","volume":"95","author":"Montes-Moreno","year":"2010","journal-title":"Haematologica"},{"issue":"10","key":"2019111702591339400_B86","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.3324\/haematol.2011.060186","article-title":"Lack and\/or aberrant localization of major histocompatibility class II (MHCII) protein in plasmablastic lymphoma","volume":"97","author":"Schmelz","year":"2012","journal-title":"Haematologica"},{"issue":"17","key":"2019111702591339400_B87","doi-asserted-by":"crossref","first-page":"9946","DOI":"10.1073\/pnas.1334037100","article-title":"Proteasome inhibitors disrupt the unfolded protein response in myeloma cells","volume":"100","author":"Lee","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2019111702591339400_B88","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1172\/JCI62973","article-title":"ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth","volume":"122","author":"Hart","year":"2012","journal-title":"J Clin Invest"},{"issue":"25","key":"2019111702591339400_B89","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1200\/JCO.2008.21.5020","article-title":"Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis","volume":"27","author":"Laurent","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111702591339400_B90","article-title":"ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements","author":"Valera","journal-title":"Mod Pathol"},{"issue":"1","key":"2019111702591339400_B91","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.humpath.2008.06.009","article-title":"Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion","volume":"40","author":"Momose","year":"2009","journal-title":"Hum Pathol"},{"issue":"5","key":"2019111702591339400_B92","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1097\/PAS.0b013e318287791f","article-title":"STAT3 Pathway Is Activated in ALK-positive Large B-cell Lymphoma Carrying SQSTM1-ALK Rearrangement and Provides a Possible Therapeutic Target","volume":"37","author":"d'Amore","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"2019111702591339400_B93","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2006.09.4490","article-title":"Immunohistochemical prognostic markers in diffuse large B-cell lymphoma:validation of tissue microarray as a prerequisite for broad clinical applications\u2013a study from the Lunenburg Lymphoma Biomarker Consortium","volume":"25","author":"De Jong","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/575\/1249699\/bep00113000575.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/575\/1249699\/bep00113000575.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T02:35:10Z","timestamp":1647657310000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2013\/1\/575\/20765\/Understanding-MYCdriven-aggressive-Bcell-lymphomas"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,6]]},"references-count":93,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2013.1.575","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,6]]}}}